647857-74-7

Usage

Uses

Used in Pharmaceutical Industry:
Methyl (R)-1-Boc-4,4-difluoropyrrolidine-2-carboxylate is used as a chiral building block for the synthesis of pharmaceuticals. Its unique structure and the Boc protecting group allow for the selective manipulation of the amine functionality, facilitating the creation of complex and biologically active molecules with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical field, Methyl (R)-1-Boc-4,4-difluoropyrrolidine-2-carboxylate is utilized as a key intermediate in the development of agrochemicals. The difluoropyrrolidine core imparts specific chemical and biological properties to the molecules, making it a valuable component in the synthesis of compounds with pesticidal or herbicidal activities.
Used in Organic Synthesis:
Methyl (R)-1-Boc-4,4-difluoropyrrolidine-2-carboxylate is employed as a versatile building block in organic synthesis. Its unique structure and functional groups make it suitable for the preparation of a wide range of organic compounds, including those with potential applications in materials science, catalysis, and other areas of chemical research.

Upstream product

• 114676-59-4 (2R,4R)-4-hydroxy-2-methoxycarbonylpyrrolidine hydrochloride 
• 114676-69-6 (2R,4R)-1-tert-butyl 2-methyl 4-hydroxypyrrolidine-1,2-dicarboxylate 
• 2584-71-6 cis-hydroxy-D-proline 
• 135042-12-5 (4R)-1-(tert-butoxycarbonyl)-4-hydroxy-D-proline 
• 256487-77-1 (R)-4-oxo-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester 

Downstream Products

• 915230-14-7 (S)-methyl-4,4-difluoropyrrolidine-2-carboxylate trifluoroacetate 
• 475561-89-8 4-fluoro-1H-pyrrole-2-carboxylic acid methyl ester 
• 536747-87-2 (R)-N-(tert-butoxycarbonyl)-4,4-difluoropyrrolidine-2-carboxylic acid 

Relevant academic research and scientific papers

COMPOUNDS TARGETING RNA-BINDING PROTEINS OR RNA-MODIFYING PROTEINS

The invention relates to a compound represented by Formula (I): or a pharmaceutically acceptable salt thereof, compositions comprising the same and methods of preparing and using the same. The variables are described herein.

MUSCARINIC AGONISTS

This invention relates to compounds that are agonists of the muscarinic M4 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1a or a salt thereof, wherein n, p, Q, R1, R2, R3, R9 and R4 are as defined herein.

HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS

Inhibitors of sepiapterin reductase of formula (I) or (I'), wherein the substituents are defined as in the claims, and uses of sepiapterin reductase inhibitors in analgesia, treatment of acute and chronic pain, anti-inflammation, and immune cell regulation are disclosed.

PHENOXYETHYL CYCLIC AMINE DERIVATIVES AND THEIR ACTIVITY AS EP4 RECEPTOR MODULATORS

The present invention provides a compound of the Formula (I): wherein X, R, R1,R2,R3, R4,R5,R6, R7, R8, and R9 are as defined herein, or a pharmaceutically acceptable salt thereof.

BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS.

This invention relates to compounds that are agonists of the muscarinic M1 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1, or a salt thereof, wherein Q, R1 , R2, R3 and R4 are as defined herein.

PYRROLIDINE GPR40 MODULATORS

The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments.

Aurora Kinase Modulators and Method of Use

The present invention relates to chemical compounds having a general formula I wherein A1-8, D′, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.

METABOTROPIC GLUTAMATE RECEPTORS 5 MODULATORS AND METHODS OF USE THEREOF

Compounds that modulate GluR5 activity and methods of using the same are disclosed.

OXADIAZOLE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF

The invention provides novel beta-secretase inhibitors and methods for their including methods of treating Alzheimer's disease.

PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES

Disclosed are compounds of Formula (I), and pharmaceutically acceptable salts thereof. The compounds of formula (I) inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.